Dr. Kostas Syrigos

School of Medicine

Athens University, Greece

Email: [email protected]

Qualifications

2002 Ph.D., Imperial College of Medicine, University of London

1995 M.D., Athens University School of Medicine

1988 B.Sc., Athens University School of Medicine

Publications (selected)

1. Cabo, H., Portillo, A., Adradas, V., et al. (2026). Spatial transcriptomic profiling to identify stroma-based prognostic groups in oncogene-addicted lung cancer. Journal of Clinical Oncology, 44(16_suppl), Article 8611.
2. Meyer, M. L., Peters, S., Jänne, P. A., et al. (2026). Global advances and future directions in lung cancer care: expert consensus and strategic priorities. ESMO Open, 11(2), Article 106034.
3. Syrigos, K. N., Bussell, M. E., Al-Shamsi, H. O., et al. (2026). Bridging the gap in lung cancer: A comprehensive global strategy for change. European Journal of Cancer, 233, Article 116069.
4. Bussell, M. E., Syrigos, K. N., Corrales, L., et al. (2025). Lung Cancer Consensus: Uniting for a Healthier World. Journal of Thoracic Oncology, 20(10_suppl), P1.17.77.
5. Skribek, M., Livanou, M. E., Vathiotis, I., et al. (2025). The BLIP Score: A Tool for Non-Small Cell Lung Cancer Patients With Brain Metastases. Journal of Thoracic Oncology, 20(10_suppl), P1.11.39.
6. Sampsonas, F., Bosgana, P., Psarros, E., et al. (2025). Geographical Inequalities and Comorbidities in the Timely Diagnosis of NSCLC: A Real-Life Retrospective Study from a Tertiary Hospital in Western Greece. Cancers, 17(16), Article 2701.
7. Mahé, I., Carrier, M., Mayeur, D., et al. (2025). Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 392(14), 1363–1373.
8. Agelaki, S., Mountzios, G., Koumarianou, A., et al. (2025). Real-world (RW) characteristics, treatment (Tx) patterns and biomarker use in patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of the retrospective INFINITY study. Journal of Thoracic Oncology, 20(3_suppl), 170P.
9. Passaro, A., Girard, N., Abreu, D. R., et al. (2025). A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7. Journal of Thoracic Oncology, 20(3_suppl), 133TiP.
10. Grapsa, D., Papadopoulou, A., Kokkotou, E., et al. (2024). Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 19(10_suppl), S331–S332.
11. Koronakis, G., Syrigos, N., Kamaratou, M. S., et al. (2024). The Prognostic Role of the Dynamic Changes in the Plasma ctDNA Levels in Advanced NSCLC after IO Initiation: A Meta-Analysis. Journal of Thoracic Oncology, 19(10_suppl), S503.
12. Papavasileiou, V., Raptakis, T., Lampadakis, S., et al. (2024). Risk Factors for the Development of Pulmonary Infection after Bronchoscopy in Patients with Lung Cancer - A Centre in Greece. Journal of Thoracic Oncology, 19(10_suppl), S484.
13. Sen, T., Evangelou, G., Sofianidi, A., et al. (2024). Clinical and Pathoanatomical Characteristics of Rare Pulmonary Neuroendocrine Tumors in Greek Population. Journal of Thoracic Oncology, 19(10_suppl), S701.
14. Tsompanellis, A., Kouvela, M., Vachlas, K., et al. (2024). The Management of Solitary Fibrous Tumors of Chest in a Center. Journal of Thoracic Oncology, 19(10_suppl), S698–S699.
15. Evangelou, G., Trontzas, I. P., Gkiozos, I., et al. (2024). The Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lungs: Insights from the LANCE Pilot Study. Biomedicines, 12(6), Article 1161.
16. Zhou, C., Levy, B. P., Sands, J., et al. (2023). TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 18(11_suppl), P2.08-01.
17. Cousin, S., Paz-Ares, L. G., Fülöp, A., et al. (2023). Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC. Journal of Clinical Oncology, 41(16_suppl), 8591.
18. Fiste, O., Liontos, M., Gavriatopoulou, M., et al. (2023). CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence. Journal of Clinical Oncology, 41(16_suppl), Article e15074.
19. Fiste, O., Liontos, M., Gavriatopoulou, M., et al. (2023). CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence. Journal of Clinical Oncology, 41(16_suppl), e15074.
20. Linardou, H., Charpidou, A., Koumarianou, A., et al. (2023). Characteristics and treatment patterns of patients with advanced or metastatic non-small cell lung cancer managed with first-line immuno-oncology strategies in Greece: Interim results of a real-world prospective study (IO-HORIZON). Journal of Thoracic Oncology, 18(4_suppl), S69–S70.

Profile Details
https://ksyrigos.gr/en/
https://scholar.google.com/citations?user=y7W4x08AAAAJ&hl=en

WOS ResearcherID: EBW-3881-2022